

*Do not enter  
SSG*

09/914,795

Berndl et al.

49727

## AMENDMENTS

### Amendments to the Claims

Please amend the claims according to the following listing of the claims.

### Listing of the Claims

1. (canceled)
2. (previously presented) A process as claimed in claim 8, wherein the molar ratio between active ingredient and cyclodextrin is in the range from 0.1 to 4.0.
3. (previously presented) A process as claimed in claim 8, wherein the plastic mixture is shaped in a molding calendar to produce the dosage forms.
4. (previously presented) A process as claimed in claim 3, wherein a molding calendar with counterrotating molding rolls is used, with at least one of the molding rolls having on its surface depressions to receive and shape the plastic mixture.
5. (previously presented) A solid dosage form which is essentially free of aliphatic C<sub>2</sub>-C<sub>8</sub>-di-and -tricarboxylic acids and aromatic C<sub>6</sub>-C<sub>10</sub>-monocarboxylic acids, obtainable by a process as claimed in claim 8.
6. (previously presented) A solid dosage form as claimed in claim 5, wherein at least 10% by weight of the active ingredient is present in the form of a cyclodextrin/active ingredient complex.
7. (previously presented) The solid dosage form of claim 5, said dosage form having release rate of active ingredient of at least 18% after 20 minutes, determined by the USP paddle method (0.1M hydrochloric acid; pH 1.0; 150 rpm).